The SARS-CoV-2 virus that causes COVID-19 may have the ability to reactivate dormant tuberculosis (TB). In a novel study scientists report in The American Journal of Pathology that infection with a specific coronavirus strain reactivated dormant Mycobacterium tuberculosis (MTB) in mice. This knowledge may help to develop new vaccines for COVID-19 and avoid a potential global tuberculosis epidemic.
A new CF treatment strategy involves small, nucleic acid molecules called oligonucleotides that can correct some of the gene defects that underlie CF but are not addressed by existing modulator therapies. The researchers used a new delivery method that overcomes traditional obstacles of getting oligonucleotides into lung cells.
What The Study Did:Â This study demonstrated an association between receiving the mRNA-1273 (Moderna) vaccine and a reduction in SARS-CoV-2 infection in health care workers beginning eight days after the first dose.
A "3D Culture System" developed by University of Southampton has closely replicated how cells infected with TB change in the human lung. Analytical evidence of these changes identified 7 key gene changes that cause damage in the lungs, from hundreds of thousands. A second trial showed that a common antibiotic, doxycycline, could help reverse these changes and speed up recovery.
Scientists have identified how and why some Covid-19 patients can develop life-threatening clots, which could lead to targeted therapies that prevent this from happening.
In this survey of 1,186 medical, graduate and health professional school faculty, more faculty considered leaving since the COVID-19 pandemic than before. Faculty with children, particularly female faculty with children, were more likely to consider leaving since the pandemic.
Below please find link(s) to new coronavirus-related content published today in Annals of Internal Medicine. All coronavirus-related content published in Annals of Internal Medicine is free to the public. A complete collection is available at https://annals.org/aim/pages/coronavirus-content.
According to AJR, high-dose intranodal lymphangiography with ethiodized oil is a safe and effective procedure for treating high-output postsurgical chylothorax with chest tube removal in 83% of patients. Previously, no data were available on the safety or benefits of injecting higher doses of ethiodized oil to treat patients with refractory postoperative chylothorax. No early or late clinically relevant complications, including symptomatic pulmonary or paradoxical embolism, were recorded for any of the patients.
The presence of Candida auris in a hospital in Salvador, Bahia, was confirmed at end-2020 and reported in an article in the Journal of Fungi. The fungus can cause a lethal invasive disease and is ringing alarm bells because of the speed with which it develops drug resistance.
Public health measures designed to reduce the spread of the COVID-19 virus may have fostered a substantial side benefit: A 53 percent drop in hospital admissions for chronic obstructive pulmonary disease (COPD), likely due to a drop in circulating seasonal respiratory viruses such as influenza.